Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:...
Cancer
EDAP Announces Second Quarter 2023 Financial Results
- Record second quarter and first half revenues of EUR 14.3 million (USD 15.5 million) and EUR 29.1 million (USD...
CancerVAX CEO Ryan Davies Discussed Cancer Immunotherapy with UCLA Physician-Scientist
Dr. Steven Jonas commented about his journey to becoming both a practicing cancer doctor and active cancer researcherLEHI, Utah, Aug....
Mithra prices private placement to raise EUR 20 million in equity
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA...
Press Release Biocartis Group NV: Biocartis Announces 2023 Half-Year Results on 26 September 2023
PRESS RELEASE: 24 August 2023, 07:00 CEST BIOCARTIS ANNOUNCES 2023 HALF-YEAR RESULTS ON 26 SEPTEMBER 2023 Mechelen, Belgium, 24 August 2023 –...
BioSenic receives a Chinese patent with broad claims, protecting the combined use of metal ions and arsenic salts to treat a wide range of serious diseases
INSIDE INFORMATION Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administrationEnriched IP...
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • 2023...
MDxHealth Reports Q2 and Half Year 2023 Results
NEWS RELEASE – REGULATED INFORMATION23 AUGUST 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Q2 and Half Year...
Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting
Pleasanton, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a...
Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression
World-first take-home approvalsThe first doses of MB22001 have been administered in an 8 week treatment protocolVANCOUVER, BC / ACCESSWIRE /...
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated...
U.S. Food and Drug Administration Approves Orphan Drug Designation for NXC-201 as a Treatment for Multiple Myeloma
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified...
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified...
Pyxis Oncology Successfully Completes Acquisition of Apexigen
Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end...
In Collaboration With JScreen, Cancer Warrior Lainie Jones Advocates for Genetic Testing
ATLANTA, GA / ACCESSWIRE / August 22, 2023 / The story of Lainie Jones, a cancer survivor from Fort Lauderdale,...
Banner Health Partners with nference to Accelerate Scientific Discovery for Patient Care
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Banner Health and nference, a science-first software company transforming healthcare by making biomedical data computable, today announced a...
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
New collaboration increases access to genetic testing and can help identify patients with a high-risk for breast cancerSALT LAKE CITY,...
SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications
REGAL Interim Analysis Expected by Late 2023/Early 2024 Enrollment Expected to be Completed in Q4 2023 NEW YORK, Aug. 22,...
Vincerx Pharma Announces FDA Clearance of IND for VIP943
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and...
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate...